



## PerkinElmer Announces New Generation in OPTIMA™ 7000 Series ICP-OES

MUNICH, Germany – PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, featured today at Analytica® 2008, April 1-4, Stand 405/504 in Hall A2, the Optima™ 7000 Series of Inductively Coupled Plasma-Optical Emissions Spectrometers (ICP-OES). The Optima ICP-OES continues to evolve to meet changing customer needs. The Optima 7000 family is designed for best-in-class inorganic analysis, and is used in a variety of markets, including environmental, geochemical, product testing and biofuels. This newest generation in the Optima series includes a Universal Data Acquisition mode that records all of the spectral data for each sample. This enables customers to retrieve data that was not initially reported without needing to run the sample again, saving them time and increasing productivity.

“We gained valuable insights from customers in a variety of markets using inorganic analysis about how we could improve our already market-leading Optima solutions to help drive even greater efficiencies in their laboratories,” said Dr. Ian Shuttler, Vice President, Inorganic Analysis, PerkinElmer Life and Analytical Sciences. “Our customers asked for the Universal Data Acquisition feature to help them decrease analysis time, since the sample does not need to be rerun.”

The Optima™ 7000 has several time-saving enhancements™ for laboratory personnel. For rapid review of results, the Optima™ 7000 generates an error flag if a sample result falls above or below a user-specified value. To ensure a consistently high level of data and without requiring additional resources, the instrumentation can automatically generate Quality Control (QC) charts that show results for analyses run over a specified period of time.

Shuttler added that the addition of modern electronics extends the instrument's lifetime, providing enhanced return-on-investment over previous technology.

The Optima™ 7000 Series replaces the Optima™ 2100, 5100, 5200 and 5300 models.

For more information visit, [www.perkinelmer.com/optima](http://www.perkinelmer.com/optima).

### Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through [www.perkinelmer.com](http://www.perkinelmer.com) or 1-877-PKI-NYSE.

“PITTCON” is a registered trademark of its owner.

For further information regarding PerkinElmer, please contact:

Ellen Wein  
Euro RSCG Worldwide PR  
(412) 456-0986

or

Lesley Sillaman  
Euro RSCG Worldwide PR  
(412) 456-7839